Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.41 +0.57 (+1.19%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
75 76 Next >
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
From Bristol Myers Squibb
Via Business Wire
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
Mental Health Mavericks: 3 Stocks Changing the Game
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
Via InvestorPlace
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
The 3 Best Stocks Beginning Investors Can Buy: February 2024
Starting your investment journey? Navigate the market with confidence! Discover 3 stocks for beginning investors in this article. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
Via Benzinga
Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside
Shares of these companies are trading at sizable earnings discounts. 
Via The Motley Fool
Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes
Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
From Bristol Myers Squibb
Via Business Wire
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Patience will be rewarded with these stocks. 
Via The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
From Bristol Myers Squibb
Via Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
From Brodsky & Smith LLC
Via GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround. 
Via InvestorPlace
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
From Bristol Myers Squibb
Via Business Wire
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
Via Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease. 
Via Investor's Business Daily
3 Blue-Chip Stocks to Buy at a 52-Week Low in February
Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price. 
Via InvestorPlace
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.